When Biogen Inc. (NASDAQ: BIIB) reported its first-quarter financial results before the markets opened on Wednesday, the firm said that it had $9.14 in earnings per share (EPS) and $3.53 billion in revenue. Analysts were calling for $7.73 in EPS and revenue $3.41 billion. The same period of last year reportedly had EPS of $6.98 on $3.39 billion in revenue.
Concerning the COVID-19 pandemic, Biogen estimates that its first-quarter product revenues benefitted by approximately $100 million, attributed to accelerated sales as a result, primarily in Europe.
[in-text-ad]
In terms of its segments, the company reported as follows:
- Multiple sclerosis (MS) revenues, including $162 million in royalties on the sales of Ocrevus, increased 9% versus the prior year to $2,280 million.
- Spinraza revenues increased 9% versus the prior year to $565 million.
- Biosimilars revenues increased 25% versus the prior year to $219 million.
- Other revenues decreased 63% versus the prior year to $109 million primarily due to the sale of approximately $200 million of hemophilia inventory to Bioverativ in the first quarter of 2019.
At the end of the quarter, Biogen had cash, cash equivalents and marketable securities totaling approximately $4.83 billion and approximately $5.96 billion in notes payable.
Biogen did not issue guidance for the second quarter. However, analysts are calling for $8.28 in EPS and $3.54 billion in revenue. Looking ahead to the full year, analysts are forecasting $32.29 in EPS and $14.06 billion in revenue.
Michel Vounatsos, Biogen’s CEO, commented:
The COVID-19 pandemic has created a challenging situation for people and companies throughout the world, and Biogen personally felt the painful impact of this global crisis. During these challenging and unprecedented times, Biogen has continued to deliver on its mission and purpose. We have continued to operate our business and deliver our therapies to patients across the world and are especially grateful to our dedicated employees as we continue to execute on our strategy.
Biogen stock traded down about 11% to $293.77 on Wednesday, in a 52-week range of $215.78 to $374.99. The consensus price target is $331.69.
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.